iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics.
IOmx Therapeutics has raised €105M across 2 funding rounds from 7 investors, most recently a Series B round in Oct 2021. Based in Munich, Germany; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2021-10-05 | Series B | €65M | Athos Service,M Ventures,MIG Capital,Sofinnova Partners,Wellington Partners | View deal → |
| 2016-09-01 | Series A | €40M | Merck Ventures,MPM Capital,Sofinnova Partners,Wellington Partners | View deal → |
